Instil Bio, Inc. announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., its wholly-owned subsidiary dedicated to the development of AXN-2510. Dr. Maraganore is a seasoned biotechnology executive with over 30 years of experience in building and leading innovative life sciences companies.
Dr. Maraganore was the founding CEO of Alnylam Pharmaceuticals, where he led the company for nearly two decades, overseeing its growth and the advancement of RNA interference (RNAi) into a validated therapeutic modality. His leadership resulted in multiple first-in-class RNAi medicines reaching the market.
His extensive experience across drug discovery, clinical development, and strategic partnering is considered invaluable for guiding the advancement of AXN-2510, Instil's potentially best-in-class PD-L1xVEGF bispecific antibody program for solid tumors. This appointment reflects Instil's commitment to assembling world-class leadership for the program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.